Progress in the medicinal chemistry of dopaminergic agents.
Ergot alkaloids and their derivatives have long been recognized for their potent pharmacologic activity. A number of ergot derivatives, including the dopamine agonists bromocriptine and pergolide, are currently in clinical use for the treatment of CNS and endocrine disorders. In an effort to develop more selective dopamine agonists, studies were directed to elucidate the dopaminergic pharmacophore of the ergoline nucleus. During the course of this work, it was found that the tricyclic system containing only the B-, C-, and D-rings of the ergoline skeleton (2, X = CH) possessed D-2 dopamine agonist activity. As a result of this discovery, interest was stimulated in the preparation of other heteroareno[g]quinoline systems (3, "BCD partial ergolines") for investigation of their dopaminergic properties. Factors which we found to be particularly important in determining dopaminergic activity were: (1) the nature of the heteroaromatic B ring; (2) the orientation of that heteroaromatic ring; (3) the substituents on the heteroaromatic ring; and (4) the relative and absolute stereochemistry at the CD ring fusion. We report here the synthesis and pharmacologic activity of a series of BCD partial ergolines (3) and describe how the study of these new compounds allows for the delineation of structural features important in D2 dopamine receptor activation.
Schaus
J M
JM
Lilly Research Laboratories, Division of Eli Lilly and Company, Indianapolis, IN 46285.
Kornfeld
E C
EC
Titus
R D
RD
Nichols
C L
CL
Huser
D L
DL
Clemens
J A
JA
Smalstig
E B
EB
Fuller
R W
RW
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000639:trends; D015259:Dopamine Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D004876:Ergot Alkaloids / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship
D015259:Dopamine Agents; D004876:Ergot Alkaloids